Natco Pharma invests $14mn in biotech firm eGenesis; total investment at $22mn
Generic drugmaker Natco Pharma is investing an additional $14 million in U.S.-based biotechnology company eGenesis, which is developing genetically engineered, human-compatible organs for transplantation. The latest investment will be made through convertible promissory notes by Natco Pharma’s subsidiaries. Natco Pharma (Canada) Inc. will invest $9.5 million, while Natco Pharma South Africa Proprietary Ltd will contribute…
Read More “Natco Pharma invests $14mn in biotech firm eGenesis; total investment at $22mn” »
